How would you approach patients receiving neoadjuvant pembrolizumab (SWOG 1801) for melanoma with no response to systemic treatment?
The SWOG 1801 trial showed improved event-free survival (EFS) in patients receiving neoadjuvant pembrolizumab followed by 15 cycles of adjuvant pembrolizumab after surgery. Do we need to consider changing pembrolizumab in the adjuvant setting if the patient does not respond to neoadjuvant treatment?
Answer from: Medical Oncologist at Academic Institution
There isn't a definitive answer to this question as patients without a pathologic response tend to have the worst outcomes in terms of relapse-free survival outcomes.
There is no prospective data to support the change in treatment strategy from single agent to dual agent, especially in the absence ...
Sign in or Register to read more